Be worried if they start getting bad results from their trials that bring into the question the validity of their underlying anti-sense technology. Otherwise, I wouldn't worry about the stock price at all, except I trade around my position so I get reduce my position on big runs up and add back to it on big runs down. If the data continues to look favorable and even a couple of these drugs get to market, this is going to be a several hundred dollar stock given the company's leverage with low operating costs, relatively few shares outstanding and little cause to have to issue more shares. In the short-term, my guess is the stock is heading to resistance at about $60.90 before heading back up for the next run.
Not sure what makes you say that. I thought Kramer gave the CEO a great opportunity and even went out of his way to try to help him out as he fumbled the opportunity. All he needed to say was that he was very encouraged by the observed increase in median time to death and ventilation dependence with the ISIS treatment and that it gives him increased confidence that the definitive P3 trial results should be positive too.
Well, at least management thinks they have an exciting story to tell at the upcoming annual meeting, or they wouldn't be putting on so much of a dog and pony show around it. Wonder if they will have the P3 SMA data and already know the results are positive?